Award for Bilobil in Poland
- Details
- Category: Product
The first place in the national competition "Consumer's Laurel 2007" in the category "Drugs for memory improvement" has been won by Krka's Bilobil. As in the last year, also this year Bilobil won the first place in its category.
Journalists from Argentina and Greece win Novo Nordisk Media Prize 2007
- Details
- Category: Novo Nordisk
Journalists Gabriela Navarra from Argentina and Michael Kefalogiannis from Greece won the Novo Nordisk Media Prize 2007 for the best article in lay press and the best TV feature about diabetes, respectively. The awards were presented by the president and CEO of Novo Nordisk, Lars Rebien Sørensen, during a ceremony held on 28 August in Copenhagen.
InferMed appoints Cancer Research UK's Dr Sally Burtles as Observer to the Board
- Details
- Category: Business
InferMed, a leading provider of advanced software solutions for clinical research and practice, has appointed Dr Sally Burtles, Director of Drug Development at Cancer Research UK, as an Observer to the Board.
InferMed has a long-standing relationship with Cancer Research UK, and was backed by the charity at its formation in 1999. A research relationship continues with Cancer Research UK, which remains InferMed's largest institutional shareholder.
Court Rules That Roche Infringes One of Amgen's Erythropoietin Patents
- Details
- Category: Amgen
Amgen (NASDAQ:AMGN) today announced that the U.S. Federal District Court in Boston granted Amgen's motion for summary judgment and ruled that Roche's pegylated-erythropoietin ("peg-EPO") product will infringe Amgen's EPO pharmaceutical composition patent number 5,955,422. In a separate decision yesterday, the Court also granted summary judgment in favor of Amgen on certain Roche defenses against the patents-in-suit.
Nexavar Significantly Improved Overall Survival in Phase III Asia-Pacific Liver Cancer Trial
- Details
- Category: Clinical Trials
Bayer HealthCare and Onyx Pharmaceuticals, Inc. today announced that a planned review by an independent data monitoring committee (DMC) found that Nexavar® (sorafenib) tablets significantly improved overall survival, progression free survival and time to progression in an Asia-Pacific regional Phase III trial of patients with advanced hepatocellular carcinoma (HCC), the most common form of liver cancer. Based on the DMC's recommendation, the trial will be stopped to allow all patients to receive treatment with Nexavar. Data from this study will be submitted for presentation at an upcoming scientific meeting.
Pfizer Names Frank A. D'Amelio Chief Financial Officer
- Details
- Category: Pfizer
Pfizer today announced that Frank A. D'Amelio, a senior executive with almost three decades of extensive operating and financial experience at AT&T, Lucent Technologies and Alcatel-Lucent, including serving as both chief operating officer and chief financial officer at Lucent, will become Pfizerâs Senior Vice President and Chief Financial Officer effective in mid-September.
Liraglutide improves glucose control and lowers body weight in two phase 3 studies
- Details
- Category: Novo Nordisk
Novo Nordisk today announced clinical results from the second and third of five phase 3 studies with liraglutide - the once-daily human GLP-1 analogue. The two 26-week studies are part of the LEAD® (Liraglutide Effect and Action in Diabetes) programme and comprised 2,132 patients in total. The two studies investigated the effect of different doses of liraglutide in combination with a single oral antidiabetic drug. Patients inadequately controlled by one or two oral antidiabetic drugs could enter the studies.
More Pharma News ...
- GlaxoSmithKline Signs Contract for its Pandemic Flu Vaccine with UK Government
- Ligand Pharmaceuticals Announces Second Quarter Results
- Santhera and Takeda Extend European Marketing Collaboration for SNT-MC17
- Availability on line of the sanofi-aventis half-year financial report for 2007
- Merck Announces Fourth Quarter 2007 Dividend
- Key business with prescription medicines continues to boost growth at Boehringer Ingelheim
- New Spiriva® Respimat® inhaler completes European approval process for COPD